Perspective: Opportunities in recalcitrant, rare and neglected tumors

Oncology Reports

Volumn 30, Issue 3, 2013, Pages 1030-1034

  Teicher, Beverly A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Neglected tumors; Pancreatic cancer; Rare tumors; Recalicitrant tumors; Sarcoma small cell lung cancer

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CASPASE 10; CISPLATIN; DEATH RECEPTOR 5; ERLOTINIB; ETOPOSIDE; FAS ANTIGEN; FAS LIGAND; GEMCITABINE; MICRORNA; TOPOTECAN;

ANGPTL2 GENE; ANTINEOPLASTIC ACTIVITY; BRAIN CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER MORTALITY; CANCER RESEARCH; CANCER SURVIVAL; CANCER THERAPY; CD24 GENE; CDK4 GENE; CELL FREE SYSTEM; CELL THERAPY; CELLULAR STRESS RESPONSE; CMET GENE; COLON CANCER; DISEASE MARKER; DNM3 GENE; DRUG MECHANISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; ENZYME MODIFICATION; EXON; FLT1 GENE; FLT4 GENE; FOXL1 GENE; FUNCTIONAL GENOMICS; GENE AMPLIFICATION; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GLI1 GENE; HDAC1 GENE; HEALTH CARE QUALITY; HEALTH PROGRAM; HIF1A GENE; HMGA2 GENE; HUMAN; IDH1 GENE; IDH2 GENE; IGFR 1 GENE; IN VIVO STUDY; JUN GENE; KDR GENE; KIDNEY CANCER; KIT GENE; LEUKEMIA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MAP3K5 GENE; MDK GENE; MDM2 GENE; MED12 GENE; MELANOMA; METASTASIS POTENTIAL; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; MUC4 GENE; MYCN GENE; NEGLECTED DISEASE; NF1 GENE; ONCOGENE; ONCOGENE MYC; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PANCREAS CANCER; PCSK1 GENE; PIK3CA GENE; PRIORITY JOURNAL; PRL GENE; PROFESSIONAL KNOWLEDGE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEOMICS; RARE DISEASE; RECALCITRANT CANCER; REVIEW; SARCOMA; SURVIVAL RATE; TEK GENE; TIE1 GENE; TIMP 2 GENE; TP53 GENE; TRANSCRIPTOMICS; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT; TUMOR SUPPRESSOR GENE; UNITED STATES; YEATS4 GENE;

ANTINEOPLASTIC AGENTS; DRUG DESIGN; HUMANS; NATIONAL INSTITUTES OF HEALTH (U.S.); NEOPLASMS; RARE DISEASES; UNITED STATES;

EID: 84880627913     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2581     Document Type: Review

References (51)

1. American Cancer Society: Cancer Facts and Figures 2011, 2012. http://www.cancer.org/research/cancerfactsfigures/cancerfactsfigures/ cancer-facts-figures-2011.
2. American Cancer Society: Lung Cancer (Small Cell), 2012. http://www.cancer.org/cancer/lungcancer-non-smallcell.
3. Socinski MA, Smit EF, Lorigan P,Konduri K, Reck M, Szczesna A, Blakely J, Serwatowski P, Karaseva NA, Ciuleanu T, Jasssem J, Dediu M, Hong S, Visseren-Grul C, Hanauske AR, Obasaju CK, Guba SC and Thatcher N: Phase II study of pemetrexed plus carboplatin compared with etoposide plus carboplatin in chemotherapy-naïve patients with extensive-stage small-cell lung cancer. J Clin Oncol 27: 4787-4792, 2009.
4. Foster NR, Qi Y, Krook JE, Kugler JW, Kuross SA, Jett JR, Molina JR, Schild SE, Adjei AA and Mandrekar SJ: Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): findings based on North Central Cancer Treatment Group (NCCTG) trials. J Clin Oncol 27 (Suppl 15): 8085, 2009.
5. van Meerbeeck JP, Fennell DA and De Ruysscher DKM: Small-cell lung cancer. Lancet 378: 1741-1755, 2011.
6. Tempero MA, Klimstra D, Berlin J, Hollingsworth T, Kim P, Merchnat N, Moore M, Pleskow D, Wang-Gillam A and Lowy AM: Changing the way we do business: recommendations to acclerate biomarker development in pancreatic cancer. Clin Cancer Res 19: 538-540, 2013.
7. Erkan M, Hausmann S, Michalski CW, Fingerle A, Dobritz M, Kleeff J and Friess H: The role of stroma in pancreatic cancer: diagnostic and therapeutic implications. Nat Rev Gastroenterol Hepatol 9: 454-467, 2012.
8. Provenzano PP, Cuevas C, Chang AE, Goel VK, Von Hoff DD and Hingorani SR: Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21: 418-429, 2012.
9. Hidalgo M: Pancreatic cancer. N Engl J Med 362: 1605-1617, 2010.
10. Teicher BA: Searching for molecular targets in sarcoma. Biochem Pharmacol 84: 1-10, 2012.
11. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
12. Oze I, Hotta K, Kiura K, Ochi N, Takigawa N, Fujiwara Y, Tabata M and Tanimoto M: Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results. PLoS One 4: e7835, 2009.
13. Johnson BE, Ihde DC, Makuch RW, Gazdar AF, Carney DN, Loe H, Russell E, Nau MN and Minna JD: myc family oncogene amplification in tumor cell lines established from small cell lung cancer patients and its relationship to clinical status and course. J Clin Invest 79: 1629-1634, 1987.
14. Johnson BE, Russell E, Simmons AM, Phelps R, Steinberg SM, Ihde DC and Gazdar AF: MYC family DNA amplification in 126 tumor cell lines from patients with small cell lung cancer. J Cell Biochem (Suppl) 24: 210-217, 1996.
15. Shivapurkar N, Reddy J, Matta H, Sathyanarayana UG, Huang CX, Toyoka S, Minna JD, Chaudhary PM and Gazdar AF: Loss expression of death-inducing signaling complex (DISC) components in lung cancer cell lines and the influence of MYC amplification. Oncogene 21: 8510-8514, 2002.
16. Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown TJ, Markovic A, Devereux WL, Ocasio CA, Chen JK, Stearns T, Thomas RK, Dorsch M, Buonamici S, Watkins DN, Peacock CD and Sage J: A critical requirement for Hedgehog signaling in small cell lung cancer. Nat Med 17: 1504-1508, 2011.
17. Watkins DN, Berman DM and Baylin SB: Hedgehog signaling: progenitor phenotype in small cell lung cancer. Cell Cycle 2: 196-198, 2003.
18. D'Angelo SP and Pietanza MC: The molecular pathogenesis of small cell lung cancer. Cancer Biol Ther 10: 1-10, 2010.
19. Su G, Burant CF, Beecher CW, Athey BD and Meng F: Integrated metabolome and transriptome analysis of the NCI60 dataset. BMC Bioinformatics 12 (Suppl 1): S36, 2011.
20. Sokilde R, Kaczkowski B, Podolska A, Cirera S, Gorodkin J, Moller S and Litman T: Global microRNA analysis of the NCI-60 cancer cell panel. Mol Cancer Ther 10: 375-384, 2011.
21. Park ES, Rabinovsky R, Carey M, Hennessy BT, Agarwal R, Liu W, Ju Z, Deng W, Lu Y, Woo HG, Kim SB, Lee JS, Garraway LA, Weinstein JN, Mills GB, Lee JS and Davies MA: Integrative analysis of proteomic signatures, mutations, and drug responsiveness in the NCI 60 cancer cell lines set. Mol Cancer Ther 9: 257-267, 2010.
22. Covell DG, Huang R and Wallqvist A: Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data. Mol Cancer Ther 6: 2261-2270, 2007.
23. Shoemaker RH: The NCI60 human tumor cell line anticancer drug screen. Nat Rev Cancer 6: 813-823, 2006.
24. Fer ND, Shoemaker RH and Monks A: Adaphostin toxicity in a sensitive non-small cell lung cancer model is mediated through Nrf2 signaling and heme oxygenase 1. J Exp Clin Cancer Res 29: 91, 2010.
25. Muus U, Hose C, Yao W, Kosakowska-Cholody T, Farnsworth D, Dyba M, Lountos GT, Waugh DS, Monks A, Burke TR Jr and Michejda CJ: Development of antiproliferative phenylmaleimides that activate the unfolded protein response. Bioorg Med Chem 18: 4535-4541, 2010.
26. Jobson AG, Lountos GT, Lorenzi PL, Connelly J, Cerna D, Tropea JE, Onda A, Zoppoli G, Kondapaka S, Zhang G, Caplen NJ, Cardellina JH, Yoo SS, Monks A, Self C, Waugh DS, Shoemaker RH and Pommier Y: Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins and radiation by the novel Chk2 inhibitor PV1019 [7-nitro-1H-indole-2-carboxylic acid {4-[1- (guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther 331: 816-826, 2009.
27. Monks A, Hose C, Pezzoli P, Kondapaka S, Vasant G, Petersen KD, Sehested M, Monteforte J and Shoemaker RH: Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs 20: 682-692, 2009.
28. Kosakowska-Cholody T, Cholody WM, Hariprakasha HK, Monks A, Kar S, Wang M, Michejda CJ and Carr BI: Growth inhibition of hepatocellular carcinoma cells in vitro and in vivo by the 8-methoxy analog of WMC79. Cancer Chemother Pharmacol 63: 769-778, 2009.
29. Martinez JM, Sali T, Okazaki R, Anna C, Hollingshead M, Hose C, Monks A, Walker NJ, Baek SJ and Eling TE: Drug-induced expression of nonsteroidal anti-inflammatory drug-activated gene/macrophage inhibitory cytokine-1/prostate- derived factor, a putative suppressor, inhibits tumor growth. J Pharmacol Exp Ther 18: 899-906, 2006.
30. Kummar S, Raffeld M, Juwara L, Horneffer Y, Strassberger A, Allen D, Steinberg SM, Rapisarda A, Spencer SD, Figg WD, Chen X, Turkbey IB, Choyke P, Murgo AJ, Doroshow JH and Melillo G: Multihistology, target-driven pilot trial of oral topotecan as an inhibitor of hypoxia-inducible factor-1α in advanced solid tumors. Clin Cancer Res 17: 5123-5131, 2011.
31. Terzuoli E, Puppo M, Rapisarda A, Uranchimeg B, Cao L, Burger AM, Ziche M and Melillo G: Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1α expression in an AhR-independent fashion. Cancer Res 70: 6837-6848, 2010.
32. Rapisarda A, Hollingshead M, Uranchimeg B, Bonomi CA, Borgel SD, Carter JP, Gehrs B, Raffeld M, Kinders RJ, Parchment R, Anver MR, Shoemaker RH and Melillo G: Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition. Mol Cancer Ther 8: 1867-1877, 2009.
33. Rapisarda A and Melillo G: Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 9: 378-390, 2012.
34. Rapisarda A and Melillo G: Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res 114: 237-267, 2012.
35. Rapisarda A and Melillo G: Combination strategies targeting hypoxia inducible factor 1 (HIF-1) for cancer therapy. In: The Tumor Microenvironment. Series: Cancer Drug Discovery and Development. Bagley RG (ed). Springer Science+Business Media, LLC 2010.
36. Onnis B, Rapisarda A and Melillo G: Development of HIF-1 inhibitors for cancer therapy. J Cell Mol Med 13: 2780-2786, 2009.
37. Rapisarda A, Shoemaker RH and Melillo G: Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle 8: 4040-4043, 2009.
38. Rapisarda A and Melillo G: Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies. Drug Resist Updat 12: 74-80, 2009.
39. Stockwin LH, Yu SX, Stotler H, Hollingshead MG and Newton DL: ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC. BMC Cancer 9: 63, 2009.
40. Stockwin LH, Han B, Yu SX, Hollingshead MG, ElSohly MA, Gul G, Slade D, Galal A and Newton DL: Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction. Int J Cancer 125: 1266-1275, 2009.
41. Stockwin LH, Yu XY, Borgel S, Hancock C, Wolfe TL, Phillips LR, Hollingshead MG and Newton DL: Sodium dichloroacetate selectively targets cells with defects in the mitochondrial ETC. Int J Cancer 127: 2510-2519, 2010.
42. Han B, Stockwin LH, Hancock C, Yu SX, Hollingshead MG and Newton DL: Proteomic analysis of nuclei isolated from cancer cell lines treated with indenoisoquinoline NSC 724998, a novel topoisomerase I inhibitor. J Proteome Res 9: 4016-4027, 2010.
43. Hancock CN, Stockwin LH, Han B, Divelbiss RD, Jun JH, Malhotra SV, Hollingshead MG and Newton DL: A copper chelate of thiosemicarbazone NSC 689534 induces oxidative/ER stress and inhibits tumor growth in vitro and in vivo. Free Radic Biol Med 50: 110-121, 2011.
44. Orsburn BC, Stockwin LH and Newton DL: Challenges in plasma membrane phosphoproteomics. Expert Rev Proteomics 8: 483-494, 2011.
45. Glaros TG, Stockwin LH, Mullendore ME, Smith B, Morrison BL and Newton DL: The survivin suppressants' NSC 80467 and YM155 induce a DNA damage response. Cancer Chemother Pharmacol 70: 207-212, 2012.
46. Ye X, Chan KC, Prieto DA, Luke BT, Johann DJ, Stockwin LH, Newton DL and Blonder J: Trypsin-mediated 18O/16O labeling for biomarker discovery. Methods Mol Biol 1002: 133-149, 2013.
47. Saini V, Hose CD, Monks A, Nagashima K, Han B, Newton DL, Millione A, Shah J, Hollingshead MG, Hite KM, Burkett MW, Delosh RM, Silvers TE, Scudiero DA and Shoemaker RH: Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma. PLoS One 7: e41401, 2012.
48. Galal AM, Gul W, Slade D, Ross SA, Feng S, Hollingshead MG, Alley MC, Kaur G and ElSohly MA: Synthesis and evaluation of dihydroartemisinin and dihydroartemisitene acetal dimers showing anticancer and antiprotozoal activity. Bioorg Med Chem 17: 741-751, 2009.
49. Kaur G, Hollingshead M, Holbeck S, Schauer-Vukasinovic V, Camalier RF, Domling A and Agarwal S: Biological evaluation of tubulysin A: a potential anticancer and antiangiogenic nautral product. Biochem J 396: 235-342, 2006.
50. Yang SX, Kummar S, Steinberg SM, Murgo AJ, Gutierrez M, Rubinstein L, Nguyen D, Kaur G, Chen AP, Giranda VL, Tomaszewski JE and Doroshow JH: Immunohistochemical detection of poly(ADP-ribose)polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas. Cancer Biol Ther 8: 2004-2009, 2009.
51. Jobson AG, Cardellina JH, Scudiero D, Kondapaka S, Zhang H, Kim H, Shoemaker R and Pommier Y: Identification of a bis-guanylhydrazone [4,4'-diacetyldiphenylurea-bis (guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Ckh2 kinase. Mol Pharmacol 72: 876-884, 2007.